Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chondrial Therapeutics licenses CTI1601 from Indiana University, Wake Forest

Executive Summary

Concurrent with a $23mm Series A financing round led by Deerfield, Chondrial Therapeutics Inc. licensed Friedreich's ataxia candidate CTI1601 and related intellectual property from Indiana University Research & Technology Corp., the technology commercialization arm of Indiana University, and Wake Forest University's tech transfer unit, Wake Forest Innovations.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies